Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

Table 5 Known-Groups Validity of Duration of MJS and Severity of MJS Using CDAI Subgroups at Week 4

PRO/Study	CDAI Category			P-value	Comparisons, ES^c
PRO/Study	0.0 to ≤10.0 N, Mean (SD), Median	>10.0 to ≤22.0 N, Mean (SD), Median	>22.0 to ≤76.0 N, Mean (SD), Median	P-value	Comparisons, ES^c
Duration of MJS Week at Week 4
RA-BEAM	220, 58.3 (95.0), 20.4	426, 90.1 (121.8), 47.1	567, 133.0 (152.8), 75.7	0.001^a	a: 0.001, 0.28; b: 0.001, 0.54; c: 0.001, 0.31
RA-BUILD	134, 70.5 (107.1), 31.4	209, 88.1 (123.3), 45.7	275, 152.9 (158.9), 95.0	0.001^a	a: 0.146, 0.15; b: 0.001, 0.57; c: 0.001, 0.45
Severity of MJS at Week 4
RA-BEAM	220, 2.3 (1.7)	426, 3.6 (2.0)	567, 5.0 (2.1)	0.001^b	a: 0.001, 0.68; b: 0.001, 1.35; c: 0.001, 0.68
RA-BUILD	134, 2.5 (1.8)	209, 3.6 (1.8)	275, 5.4 (2.0)	0.001^b	a: 0.001, 0.61; b: 0.001, 1.50; c: 0.001, 0.94

Abbreviations: CDAI Clinical Disease Activity Index, MJS morning joint stiffness, SD standard deviation, ES effect size
^a p-value based on a comparison of median values using the Kruskal-Wallis test
^b p-value based on a comparison of mean values using analysis of variance
^cNote for multiple comparison using Scheffé adjustment: a: 0.0 to ≤10.0 versus >10.0 to ≤22.0; b: 0.0 to ≤10.0 versus >22.0 to ≤76.0; c: >10.0 to ≤22.0 versus >22.0 to ≤76.0. Effect size estimates were calculated on the unadjusted group scores

ISSN: 1477-7525